Read the December 11th issue of Chain Drug Review, which includes a special section commemorating the 90th anniversary of the founding of the National Association of Chain Drug Stores. The 56-page section is presented by CDR, Drug Store News and the Emerson Group.
Read the December 11th issue of Chain Drug Review, which includes a special section commemorating the 90th anniversary of the founding of the National Association of Chain Drug Stores. The 56-page section is presented by CDR, Drug Store News and the Emerson Group. Here is the link for the issue: http://digitaledition.chaindrugreview.com/publication/?i=809929. The section begins on page 11.
How is the pharmaceutical value chain faring financially? Who are the biggest winners and losers? Every two years, Kearney analyzes pharmaceutical profit pools to answer those questions. Our analysis follows a drug across the value chain, from concept to patient.
As the start of a new year approaches, long-standing trends are raising the stakes for big pharmacy operators and other companies with the ambition to re-engineer a health care system plagued by chronic issues of access, quality and cost.
This is an especially special holiday season for participants in and advocates of chain drug retailing in America. Reason? The season celebrates and pauses to recall the 90th anniversary of the National Association of Chain Drug Stores.
Dinakaran (Dina) Balasubramanian, head of commercial strategy and insights for biologics at Dr. Reddy’s Laboratories, spoke with Chain Drug Review about his role at the drug maker and how specialty generic drugs and biosimilars are fueling growth for it.
Kantar’s David Marcotte noted that year-over-year continuity at the top underscores the market dominance of large-format retailers and vertically integrated omnichannel players.
The Journal reported that WK Kellogg shareholders will receive $23 per share in cash—representing a premium of roughly 40% over recent trading levels. Including debt, the transaction gives WK Kellogg a total enterprise value of about $3.1 billion.
Systemic changes like those in the PBM Reform Act must pass and be enacted as soon as possible. We’re grateful for this bill’s introduction and will do everything we can to push it across the finish line.”
The bill establishes powerful transparency requirements, bans spread pricing, assures fair reimbursement for pharmacies, and tackles anti-competitive practices that have driven up drug costs and limited patient choice.
